Trial Profile
English Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2022
Price :
$35
*
At a glance
- Drugs Tedizolid (Primary)
- Indications Bone and joint infections
- Focus Therapeutic Use
- Acronyms PROTEDI
- 04 Feb 2020 Planned End Date changed from 30 Sep 2021 to 28 Feb 2022.
- 04 Feb 2020 Planned primary completion date changed from 1 Nov 2020 to 1 Mar 2021.
- 04 Feb 2020 Planned initiation date changed from 1 Nov 2019 to 1 Mar 2020.